GlassScriptPhysician profile
Jared David York
NPI 1124332168
$4,015.41
in general payments reported to CMS, 2019-2025
29 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $701 · 2023: $865 · 2024: $978 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $728.67 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $626.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $319.21 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.46 | 2022-2025 | Jardiance |
| Pfizer INC. | $223.39 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.44 | 2022-2025 | Trintellix |
| Abbott Laboratories | $186.00 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $179.35 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Dexcom, INC. | $142.83 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $136.11 | 2023-2025 | Veozah, Myrbetriq |
| Corcept Therapeutics | $131.14 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $117.31 | 2022-2025 | Rexulti |
| Inspire Medical Systems, INC. | $91.22 | 2024 | Inspire |
| Lundbeck LLC | $77.06 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $75.84 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.61 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $57.05 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Glaxosmithkline, LLC. | $47.66 | 2022-2025 | Arexvy, Shingrix |
| Dynavax Technologies Corporation | $37.84 | 2023-2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $34.59 | 2022 | |
| Biogen, INC. | $25.84 | 2025 | Skyclarys |
| Seqirus USA INC | $21.17 | 2025 | Fluad, Flucelvax |
| Teva Pharmaceuticals USA, INC. | $17.56 | 2022 | |
| Amgen INC. | $16.38 | 2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $15.38 | 2023 | Eliquis |
| Ultragenyx Pharmaceutical INC. | $15.17 | 2022 | |
| Merck Sharp & Dohme LLC | $14.71 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared York listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.